Search
for

    Sort by

    Community Join

    450-480 / 1000+ results

      community 1 year after fin/RU and 3000 grafts.

      in Progress Pictures  19 upvotes 1 year ago
      The user shared progress pictures showing significant improvement in hair loss after using finasteride, RU58841, and undergoing a 3000 graft hair transplant. They plan to get another transplant due to remaining thin areas.

      community Ru58841 after a hair transplant

      in Transplants  7 upvotes 1 year ago
      A user discussed their hair transplant progress and mentioned using 1mg Finasteride, 5% Topical Minoxidil, and recently starting 5% RU58841. They are seeking advice on whether to use RU58841 at month 4 post-transplant.

      community is RU worth it if you already take dut and min?

      in Chat  3 upvotes 2 months ago
      A user taking dutasteride and minoxidil for hair loss is considering adding RU58841 to their regimen due to unsatisfactory results. Other users suggest alternatives and discuss the potential temporary benefits and limitations of RU58841.

      community 1 year Fin/Min + sporadic use of RU58841 (a few months here or there)

      in Progress Pictures  106 upvotes 4 years ago
      The conversation is about a person's one-year progress using finasteride and minoxidil for hair loss, with intermittent use of RU58841, showing improved hair quality, density, and thickness without side effects. Users complimented the improved appearance and suggested the longer hair also enhanced their look.

      community So... any chinese suppliers for real pyri?

      in Research/Science  6 upvotes 1 year ago
      The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

      community First bottle of Morr-F arrived. Wish me luck, and an introduction.

       15 upvotes 7 years ago
      A user discusses their experience with hair loss and treatments, including minoxidil, micro needling, rosemary oil, dietary supplements, and topical finasteride (Morr-F). They emphasize the impact of lifestyle on hair health and express hope for improvement with the new treatment.

      community Lowest Effective RU58841 Dose?

      in Treatment  4 upvotes 1 year ago
      RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

      community Anyone get results with Ru58841?

      in Treatment  6 upvotes 3 months ago
      RU58841 stopped shedding after two weeks and improved hair after eight months. Initial thinning may occur within the first month.

      community any females on RU58841/minoxidil 2.5%?

      in Minoxidil  6 upvotes 4 years ago
      A female user is considering using RU58841 with minoxidil 2.5% to reduce side effects like facial hair from minoxidil 5%, while also using copper peptides and a hair serum. Other users discuss alternative treatments like spironolactone, alfatradiol, and the side effects of finasteride.

      community Nuclear topical fin formulation?

      in Chat  1 upvotes 8 months ago
      The conversation discusses a hair loss treatment involving oral minoxidil, topical finasteride, and a custom topical formulation with minoxidil, cetirizine, finasteride, progesterone, and hydrocortisone. The user seeks advice on the effectiveness of these ingredients for diffuse thinning.

      community Aesthetic Cosmetics RU8841 real or not? Australia RU

      in Treatment  1 upvotes 2 years ago
      A user switched from Anageninc to Aesthetic Cosmetics for RU58841 and experienced increased shedding, questioning the product's authenticity. They seek advice on reliable sources for RU58841 in Australia.

      community HMI-115 question about potential earliest access

      in Research/Science  10 upvotes 3 years ago
      Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

      community Pp405 phase 2a clinical results

      in Research/Science  40 upvotes 11 months ago
      PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

      community Minoxidilmax vs Morr-F

      in Product  11 upvotes 6 years ago
      The user is considering two hair loss treatments: Minoxidilmax Maxogen-x, which contains Minoxidil, Finasteride, Azelaic Acid, ABN Complex, Retinoic Acid, Fluocinolone, and Caffeine, and Morr-F, which contains only Minoxidil and Finasteride. They are asking for others' experiences with these brands.

      community Clascoterone full results in July

      in Research/Science  13 upvotes 3 weeks ago
      Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

      community Mechanism of action of alfatradiol (17 alpha estradiol)

      in Research/Science  5 upvotes 2 years ago
      The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.

      community FOL005 claims it's better than Finasteride and Minoxidil.

      in Technology  184 upvotes 1 year ago
      FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.